In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 
Gilles Montalescot
Speaker
Gilles Montalescot
Gilles Montalescot Gilles Montalescot

Hospital Pitie-Salpetriere, Paris (France)

Specialities : Interventional Cardiology , Atrial Fibrillation, Pharmacology and Pharmacotherapy

Gilles Montalescot is Professor of Cardiology at the Pitié-Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years. Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr. Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, and the ongoing ATLANTIS, ALPHEUS, ARAMIS, ADRIFT trials. Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié-Salpêtrière Hospital in Paris

47 presentations from this speaker

Advancing patient care with NOACs in other cardiac interventions

Event : ESC Congress 2019

  • Session : Non-vitamin K antagonist oral anticoagulants (NOACs): from new evidence to improved patient outcomes in atrial fibrillation
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by The Bristol-Myers Squibb/Pfizer Alliance

Case clinic - Treating the patient who needs more

Event : ESC Congress 2019

  • Session : Vascular protection - Which of your patients with chronic coronary artery disease will benefit?
  • Speaker : G Montalescot (Paris,FR), R Welsh (Edmonton,CA)
  • Sponsored by Bayer AG

Case clinic: What would you do?

Event : ESC Congress 2019

  • Session : Vascular protection: when do patients need more?
  • Speaker : G Montalescot (Paris,FR), K Fox (Edinburgh,GB)
  • Sponsored by Bayer AG

Discussant review - ISAR-REACT 5

Event : ESC Congress 2019

  • Session : Hot Line Session 2
  • Speaker : G Montalescot (Paris,FR)

Guideline update

Event : ESC Congress 2019

  • Session : Vascular protection: when do patients need more?
  • Speaker : K Fox (Edinburgh,GB), G Montalescot (Paris,FR)
  • Sponsored by Bayer AG

Low-dose rivaroxaban after left atrial appendage closure: The randomized ADRIFT study

Event : ESC Congress 2019

  • Session : Late Breaking Science in Intervention
  • Speaker : G Montalescot (Paris,FR)

P2Y12 inhibition should be started at the time of NSTEMI diagnosis - CON.

Event : ESC Congress 2019

  • Session : Controversies in anti-platelet therapy
  • Speaker : G Montalescot (Paris,FR)

User experience from an acute cardiac care department

Event : ESC Congress 2019

  • Session : Innovations in digital medicine
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by WeHealth Digital Medicine

Welcome and introduction

Event : ESC Congress 2019

  • Session : Vascular protection: when do patients need more?
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by Bayer AG

Welcome and objectives

Event : ESC Congress 2019

  • Session : Non-vitamin K antagonist oral anticoagulants (NOACs): from new evidence to improved patient outcomes in atrial fibrillation
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by The Bristol-Myers Squibb/Pfizer Alliance

Aspirin after stenting - Do we still need it?

Event : ESC Congress 2018

  • Session : Safer stents and strategies: is it time for the de-escalation of dual antiplatelet treatment regimes?
  • Speaker : G Montalescot (Paris,FR)

TAVI with atrial fibrillation: which antithrombotic regimen?

Event : ESC Congress 2017

  • Session : Tough decisions around TAVI
  • Speaker : G Montalescot (Paris,FR)

When should we start P2Y12 inhibitors in patients with an acute coronary syndrome?

Event : ESC Congress 2017

  • Session : Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS
  • Speaker : G Montalescot (Paris,FR)

ANTARCTIC - Platelet function monitoring in elderly patients stented for an acute coronary syndrome

Event : ESC Congress 2016

  • Session : Hot Line preventive strategies 1
  • Speaker : G Montalescot (Paris,FR)

Management of acute coronary syndromes

Event : ESC Congress 2016

  • Session : The European Heart Journal's Year in Cardiology: from prevention to intervention
  • Speaker : G Montalescot (Paris,FR)
  • Joint with the European Heart Journal

Managing angina: why more needs to be done?

Event : ESC Congress 2016

  • Session : Going further in treatment of angina with ivabradine
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by SERVIER

Discussion - Summary and closing remarks - Dual antiplatelet treatment duration in Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?

Event : ESC Congress 2015

  • Session : Dual antiplatelet treatment duration in Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by Daiichi Sankyo Europe GmbH

Early aldosterone blockade in acute myocardial infarction: the randomised ALBATROSS Trial.

Event : ESC Congress 2015

  • Session : Meet the Trialist I: ALBATROSS
  • Speaker : G Montalescot (Paris,FR)

Early aldosterone blockade in acute myocardial infarction: the randomized ALBATROSS Trial

Event : ESC Congress 2015

  • Session : Hot Line I - Acute myocardial infarction
  • Speaker : G Montalescot (Paris,FR)

Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: the ATLANTIC-H24 analysis

Event : ESC Congress 2015

  • Session : Clinical Trial Update II - Antiplatelet therapy
  • Speaker : G Montalescot (Paris,FR)

Introduction - Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?

Event : ESC Congress 2015

  • Session : Dual antiplatelet treatment duration in Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by Daiichi Sankyo Europe GmbH

Optimising oral anticoagulation in routine clinical practice.

Event : ESC Congress 2015

  • Session : Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by BMS-Pfizer Alliance

Chairs' introduction: improving patient care, a joint commitment.

Event : ESC Congress 2014

  • Session : Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition
  • Speaker : H Bueno (Madrid,ES), G Montalescot (Paris,FR)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Differential approach for early adjuvant therapy - Is early always better?

Event : ESC Congress 2014

  • Session : Controversies in high-risk PCI - Future directions for early adjuvant therapies
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by Cardiome International AG

New antithrombotics beyond clopidogrel in stable coronary artery disease: why and when?

Event : ESC Congress 2014

  • Session : Antiplatelet treatment in stable coronary artery disease patients
  • Speaker : G Montalescot (Paris,FR)

P2Y12 inhibitors should be withheld prior to angiography in NSTE-ACS. PRO.

Event : ESC Congress 2014

  • Session : Optimal antithrombotic strategies in acute coronary syndrome
  • Speaker : G Montalescot (Paris,FR)

P2Y12 inhibitors should be withheld prior to angiography in NSTE-ACS. REBUTTAL PRO.

Event : ESC Congress 2014

  • Session : Optimal antithrombotic strategies in acute coronary syndrome
  • Speaker : G Montalescot (Paris,FR)

Panel discussion: the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: are we getting there?

Event : ESC Congress 2014

  • Session : Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition
  • Speaker : G Montalescot (Paris,FR), A Goette (Paderborn,DE), J Alexander (Durham,US), P Kirchhof (Edgbaston,GB), S Connolly (Hamilton,CA)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Pre-treatment with P2Y12 inhibitors in acute coronary syndrome. CONTRA.

Event : ESC Congress 2014

  • Session : Anticoagulants and antiplatelets - new perspectives
  • Speaker : G Montalescot (Paris,FR)

Pre-treatment with P2Y12 inhibitors in acute coronary syndrome. REBUTTAL CONTRA.

Event : ESC Congress 2014

  • Session : Anticoagulants and antiplatelets - new perspectives
  • Speaker : G Montalescot (Paris,FR)

TASTE: Discussant review

Event : ESC Congress 2014

  • Session : Clinical Trial Update Hot Line: Infarction, interventions and outcome
  • Speaker : G Montalescot (Paris,FR)

Contra.

Event : ESC Congress 2013

  • Session : Bivalirudin is the ideal anticoagulant in percutaneous coronary intervention for high-risk acute coronary syndrome.
  • Speaker : G Montalescot (Paris,FR)

Contra.

Event : ESC Congress 2013

  • Session : Bivalirudin is the ideal anticoagulant in percutaneous coronary intervention for high-risk acute coronary syndrome.
  • Speaker : G Montalescot (Paris,FR)

New therapeutic paradigms for optimizing cardiovascular risk reduction in patients with type 2 diabetes: the pivotal role of multifactorial cardiometabolic-focused interventions .

Event : ESC Congress 2013

  • Session : New frontiers, novel mechanisms, and evolving paradigms for optimizing cardiovascular risk reduction in patients with type 2 diabetes and acute coronary syndrome
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by Roche

Pro.

Event : ESC Congress 2013

  • Session : Every patient with non ST-elevation myocardial infarction should be treated with ticagrelor.
  • Speaker : G Montalescot (Paris,FR)

Pro.

Event : ESC Congress 2013

  • Session : Closure of the left atrial appendage will replace anticoagulation for patients with atrial fibrillation.
  • Speaker : G Montalescot (Paris,FR)

Pro.

Event : ESC Congress 2013

  • Session : Every patient with non ST-elevation myocardial infarction should be treated with ticagrelor.
  • Speaker : G Montalescot (Paris,FR)

Pro.

Event : ESC Congress 2013

  • Session : Closure of the left atrial appendage will replace anticoagulation for patients with atrial fibrillation.
  • Speaker : G Montalescot (Paris,FR)

Stable coronary artery disease.

Event : ESC Congress 2013

  • Session : ESC Guidelines 2013 overview
  • Speaker : U Sechtem (Stuttgart,DE), G Montalescot (Paris,FR)

Stable coronary artery disease: questions and answers to the panellists.

Event : ESC Congress 2013

  • Session : Meet the Guidelines Task Force I
  • Speaker : U Sechtem (Stuttgart,DE), G Montalescot (Paris,FR)

The association of pretreatment with clinical outcomes in patients undergoing PCI.

Event : ESC Congress 2013

  • Session : Early initiation of antiplatelet therapy: pre-treatment in ACS, facts and fictions
  • Speaker : G Montalescot (Paris,FR)
  • Organised by Leiden University Medical Centre / Course Director: Prof. Wouter Jukema / Programme supported by an unrestricted educational grant from Daiichi Sankyo and Eli Lilly and Company

Trial update on the fancy new drugs in STEMI.

Event : ESC Congress 2013

  • Session : STEMI management: the fancy and the reality
  • Speaker : G Montalescot (Paris,FR)
  • Sponsored by Pfizer

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are